Fate Therapeutics, Inc.

    Jurisdiction
    United States
    LEI
    549300L14Q4UHOODLA90
    ISIN
    US31189P1021 (FATE)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    50 / 100
    Even with peer group:
    51 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    3 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    6 / 7

    Profile

    Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Read full profile

    Fundamentals

    Net revenue
    €7.22M
    Gross margin
    61.3%
    EBIT
    -€164.08M
    EBIT margin
    -2,271.2%
    Net income
    -€146.30M
    Net margin
    -2,025.1%

    Statement period: - (published )

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    TAHL CINDY See Remarks -9K $1.06 -$9.58K
    Valamehr Bahram President and CEO -14K $1.06 -$15.33K

    Earnings Calls

    Earnings Calls

    Latest earnings call: May 9, 2024 (Q1 2024)

    Add to watchlist

    Notifications